Arrowhead Pharmaceuticals Corp (ARWR) Reports In-Line Q3 EPS, Revenues Beat
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $82.00 +0.22%
Revenue Growth %: +89.5%
Financial Fact:
NET INCOME (LOSS) ATTRIBUTABLE TO ARROWHEAD: -19.42M
Today's EPS Names:
JFIN, KEQU, LASE, More
Revenue Growth %: +89.5%
Financial Fact:
NET INCOME (LOSS) ATTRIBUTABLE TO ARROWHEAD: -19.42M
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q3 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $727.38 thousand versus the consensus estimate of $690 thousand.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- MP Materials seen largely insulated after China export-control move
- JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
